A high-salt diet can blunt the blood-pressure-lowering effect of any antihypertensive, including Beloc. While the medication will still work, achieving target blood pressure may be more difficult. Reducing dietary sodium is recommended alongside therapy.
Some decongestants (e.g., pseudoephedrine) have sympathomimetic activity that can raise heart rate and blood pressure, potentially counteracting Beloc’s effects. Use caution and discuss with a pharmacist before combining.
In the UK, Beloc 20 mg tablets typically bear the imprint “20 B” and Beloc 40 mg tablets “40 B”. However, imprint styles may vary by manufacturer; always verify with the packaging.
Metoprolol is not on the World Anti-Doping Agency (WADA) prohibited list, but athletes may need to declare its use to avoid therapeutic use exemption (TUE) complications.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be aware of any country-specific import restrictions for prescription drugs.
Metoprolol can mask typical signs of hypoglycaemia (e.g., rapid heart rate). Diabetic patients should monitor glucose levels more closely and remain aware of this effect.
Prolonged exposure to high temperatures can degrade the tablet’s active ingredient. Store Beloc in a cool, dry place and avoid leaving it in a vehicle on hot days.
Yes, metoprolol tartrate is available as a generic tablet from multiple UK pharmacies, often listed simply as “Metoprolol Tartrate 20 mg” or “40 mg”. The therapeutic effect is equivalent when the dosage matches.
Sit or lie down immediately, raise your legs if possible, and seek medical attention if symptoms persist (e.g., dizziness, fainting, blurred vision). Do not adjust the dose without consulting your prescriber.
Combination therapy is common for resistant hypertension. Beloc may be safely combined with ACE inhibitors, ARBs, thiazide diuretics, or calcium-channel blockers, but dose adjustments and close monitoring are required to avoid excessive hypotension.
Beloc is a brand-name medication that contains metoprolol tartrate as its active ingredient. It belongs to the heart & blood pressure therapeutic class and is formulated as an oral pill. In the United Kingdom Beloc is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is available in two strengths: 20 mg and 40 mg tablets.
Metoprolol tartrate is a selective β1-adrenergic blocker. By inhibiting the action of adrenaline and noradrenaline on cardiac β1 receptors, Beloc helps to lower heart rate, reduce myocardial contractility, and decrease blood pressure. These effects make it useful for several cardiovascular conditions, which are detailed below.
Metoprolol tartrate exerts its therapeutic effect through the following mechanisms:
β1-receptor antagonism - The drug binds selectively to β1 receptors located primarily in the heart. This blocks the normal response to endogenous catecholamines, leading to a slower heart rate (negative chronotropy) and reduced force of contraction (negative inotropy).
Reduced renin release - β1-blockade in the juxtaglomerular cells of the kidney diminishes renin secretion, which in turn lowers angiotensin-II and aldosterone levels, contributing to blood-pressure reduction.
Decreased cardiac oxygen demand - By lowering heart rate and contractility, the heart works more efficiently and requires less oxygen, which helps relieve angina (chest pain due to insufficient blood flow).
Stabilisation of cardiac rhythm - The slowed conduction through the atrioventricular (AV) node can suppress certain arrhythmias, particularly supraventricular tachycardias.
The onset of action after an oral dose typically occurs within 1 hour, with peak plasma concentrations reached at about 2 hours. The half-life of metoprolol tartrate is approximately 3-4 hours, which is why dosing is usually once daily for Beloc.
Beloc is approved by the MHRA for the following indications:
These uses are supported by large clinical trials and are reflected in the product’s Summary of Product Characteristics (SPC) in the UK.
Some clinicians prescribe metoprolol for conditions that are not formally approved by the MHRA but have supporting evidence:
Disclaimer: Off-label use of Beloc must be supervised by a qualified healthcare professional, with a careful risk-benefit assessment for each individual patient.
Patients with any of the above conditions should discuss alternative therapies or dose adjustments with their prescriber.
Black-Box Warnings: None are required for metoprolol tartrate in the UK, but the SPC highlights the risk of abrupt withdrawal leading to rebound hypertension and tachycardia.
| Interaction Type | Examples | Clinical Implication | ||-|-| | Major | Verapamil, diltiazem (non-DHP calcium-channel blockers) | Additive negative chronotropic effect → may cause severe bradycardia or AV block. | | | Paroxetine, quinidine (strong CYP2D6 inhibitors) | Increases metoprolol plasma concentrations → higher risk of hypotension/bradycardia. | | | Insulin, oral hypoglycaemics | May mask hypoglycaemic symptoms; monitor glucose closely. | | Moderate | Other β-blockers (e.g., atenolol) | Additive β-blockade - consider dose reduction. | | | Clonidine | Concomitant use can cause marked hypotension; taper clonidine before stopping. |
Patients should always disclose all current medications, including over-the-counter drugs and herbal supplements, to their prescriber.
Regular review appointments (typically every 4-6 weeks after initiation or dose change) allow the clinician to assess efficacy, tolerability, and need for further adjustments.
This article provides educational information about Beloc and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
